Veeva Systems Inc. (NYSE:VEEV) Shares Acquired by Blair William & Co. IL

Blair William & Co. IL lifted its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 0.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,216,231 shares of the technology company’s stock after purchasing an additional 3,608 shares during the quarter. Veeva Systems comprises approximately 0.7% of Blair William & Co. IL’s holdings, making the stock its 27th largest holding. Blair William & Co. IL owned approximately 0.75% of Veeva Systems worth $255,713,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB increased its position in shares of Veeva Systems by 72.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock worth $25,000 after acquiring an additional 50 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in Veeva Systems during the 4th quarter worth $25,000. Smithfield Trust Co increased its holdings in Veeva Systems by 145.5% in the 4th quarter. Smithfield Trust Co now owns 135 shares of the technology company’s stock valued at $27,000 after purchasing an additional 80 shares in the last quarter. True Wealth Design LLC raised its position in Veeva Systems by 3,375.0% in the third quarter. True Wealth Design LLC now owns 139 shares of the technology company’s stock valued at $29,000 after purchasing an additional 135 shares during the period. Finally, Avion Wealth lifted its stake in shares of Veeva Systems by 635.0% during the fourth quarter. Avion Wealth now owns 147 shares of the technology company’s stock worth $30,000 after purchasing an additional 127 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on VEEV. Evercore ISI increased their target price on Veeva Systems from $220.00 to $245.00 and gave the company an “in-line” rating in a research note on Friday, December 6th. Robert W. Baird lifted their price objective on shares of Veeva Systems from $283.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, March 6th. Bank of America upped their target price on shares of Veeva Systems from $280.00 to $290.00 and gave the company a “neutral” rating in a research note on Friday, December 6th. JPMorgan Chase & Co. lifted their price target on shares of Veeva Systems from $218.00 to $249.00 and gave the stock a “neutral” rating in a research note on Thursday, March 20th. Finally, The Goldman Sachs Group cut shares of Veeva Systems from a “buy” rating to a “sell” rating and decreased their price objective for the company from $261.00 to $200.00 in a research report on Thursday, January 23rd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Veeva Systems currently has an average rating of “Moderate Buy” and an average price target of $256.52.

Veeva Systems Stock Performance

Veeva Systems stock opened at $235.52 on Thursday. Veeva Systems Inc. has a one year low of $170.25 and a one year high of $258.93. The company has a 50-day simple moving average of $230.82 and a 200-day simple moving average of $222.68. The firm has a market capitalization of $38.24 billion, a P/E ratio of 58.15, a P/E/G ratio of 1.89 and a beta of 0.88.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.